PMID- 30474386
OWN - NLM
STAT- MEDLINE
DCOM- 20200205
LR  - 20211204
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 24
IP  - 3
DP  - 2019 May
TI  - Employing the Sirolimus-Eluting Poly (Propylene Carbonate) Mesh for the 
      Prevention of Arteriovenous Graft Stenosis in Rats.
PG  - 269-277
LID - 10.1177/1074248418806060 [doi]
AB  - Poly (propylene carbonate, PPC) is a new member of the aliphatic polyester 
      family. An outstanding feature of PPC is that it produces mainly water and carbon 
      dioxide when degraded in vivo, causing minimal side effects. This unique property 
      together with excellent biocompatibility and biodegradability makes PPC a 
      promising material for drug delivery. In this study, we explored the effect of 
      the sirolimus (an inhibitor of cell growth)-eluting PPC mesh on graft stenosis 
      and its possible mechanisms in a rat arteriovenous grafting model. The PPC mesh 
      was prepared by electrospinning. A jugular vein to abdominal aortic autograft 
      transplantation model was established in rats. The graft was then treated by 
      wrapping with the drug mesh or the drug-free mesh or left untreated. Four weeks 
      posttransplantation, neointima was measured with hematoxylin and eosin staining, 
      matrix metalloproteinase-2 (MMP-2), and MMP-9, and proliferating cell nuclear 
      antigen (PCNA) in the grafts were assayed by Western blotting and 
      immunohistochemistry, respectively. In vitro rat aortic adventitial fibroblast 
      cell (RAAFC) migration was assessed using the Boyden chamber assay, and 
      phospho-mammalian target of rapamycin (mTOR) levels in RAAFCs were determined by 
      Western blotting. Animals with the drug mesh had an intimal area index of 4.87% +/- 
      0.98%, significantly lower than that of the blank group (14.21% +/- 2.56%) or the 
      PPC group (15.03% +/- 2.35%, both P < .05). The sirolimus mesh markedly suppressed 
      MMP-2 and MMP-9 expression, decreased PCNA-positive cell numbers, inhibited RAAFC 
      migration, and reduced phospho-mTOR levels. Our data suggest that the 
      sirolimus-eluting PPC mesh might be potentially applied for the management of 
      grafting stenosis.
FAU - Sun, Hourong
AU  - Sun H
AD  - 1 Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, 
      Jinan, Shandong, China.
FAU - Liu, Chuan-Zhen
AU  - Liu CZ
AD  - 1 Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, 
      Jinan, Shandong, China.
FAU - Liu, Chunxiao
AU  - Liu C
AD  - 1 Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, 
      Jinan, Shandong, China.
FAU - Tang, Mengmeng
AU  - Tang M
AD  - 1 Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, 
      Jinan, Shandong, China.
FAU - Cao, Guangqing
AU  - Cao G
AD  - 1 Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, 
      Jinan, Shandong, China.
FAU - Zhang, Qiuwang
AU  - Zhang Q
AD  - 2 Division of Cardiology, Keenan Research Center for Biomedical Science, St. 
      Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
FAU - Gu, Xinghua
AU  - Gu X
AUID- ORCID: 0000-0003-2175-6870
AD  - 1 Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, 
      Jinan, Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181126
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Coated Materials, Biocompatible)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 8D08K3S51E (propylene carbonate)
RN  - EC 2.7.1.1 (mTOR protein, rat)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.24 (Mmp2 protein, rat)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - EC 3.4.24.35 (Mmp9 protein, rat)
RN  - T75W9911L6 (Propane)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Aorta, Abdominal/*surgery
MH  - Autografts
MH  - Cardiovascular Agents/*administration & dosage
MH  - Cell Movement
MH  - *Coated Materials, Biocompatible
MH  - Equipment Design
MH  - Fibroblasts/metabolism/pathology
MH  - Graft Occlusion, Vascular/metabolism/pathology/physiopathology/*prevention & 
      control
MH  - Jugular Veins/metabolism/pathology/physiopathology/*transplantation
MH  - Male
MH  - Matrix Metalloproteinase 2/metabolism
MH  - Matrix Metalloproteinase 9/metabolism
MH  - Phosphorylation
MH  - Proliferating Cell Nuclear Antigen/metabolism
MH  - Propane/*analogs & derivatives
MH  - Rats, Wistar
MH  - Sirolimus/*administration & dosage
MH  - *Surgical Mesh
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Vascular Grafting/adverse effects/*instrumentation
MH  - Vascular Patency
OTO - NOTNLM
OT  - arteriovenous grafting
OT  - cell migration
OT  - intimal hyperplasia
OT  - matrix metalloproteinase
OT  - poly (propylene carbonate)
OT  - sirolimus
OT  - stenosis
EDAT- 2018/11/27 06:00
MHDA- 2020/02/06 06:00
CRDT- 2018/11/27 06:00
PHST- 2018/11/27 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
PHST- 2018/11/27 06:00 [entrez]
AID - 10.1177/1074248418806060 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2019 May;24(3):269-277. doi: 
      10.1177/1074248418806060. Epub 2018 Nov 26.